Last updated: February 16, 2026
What Is NDC 58914-0501?
NDC 58914-0501 is Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years old. As a one-time therapy, Zolgensma addresses genetic causes of SMA by delivering a functional copy of the defective gene.
Current Market Landscape
Market Size and Incidence
- SMA affects approximately 1 in 10,000 live births globally. In the U.S., an estimated 350 to 400 infants are diagnosed annually (Sources: FDA, SMA Foundation).
- The pediatric SMA population eligible for Zolgensma comprises all infants diagnosed before age 2, roughly 250–350 annually in the U.S.
Market Penetration
- Since approval in May 2019, Zolgensma has gained approved access in key markets including the U.S., EU, and Japan.
- As of 2022, estimated U.S. sales reach approximately $2.7 billion, with growth driven by expanding indications and improved diagnosis rates.
Competitive Landscape
- Spinraza (nusinersen) remains the primary alternative, administered via intrathecal injections.
- Other gene therapies remain in development, but none have achieved commercial availability comparable to Zolgensma.
Pricing Structure and Revenue
Price Point
- The list price of Zolgensma in the U.S. is approximately $2.1 million per treatment (Sources: Novartis financial disclosures, 2022).
- This pricing aligns with the therapy’s one-time administration model, targeting lifelong treatment costs for SMA.
Reimbursement and Payer Dynamics
- Major payers, including Medicare and private insurers, negotiate discounts and value-based arrangements.
- The high upfront cost is offset by the potential for reduced long-term healthcare expenses in SMA management.
Market Projection Analysis
Short-Term (Next 2-3 years)
- Market growth forecasted at 10–15% annually, driven by increased diagnosis, broader pediatric access, and expanded indications.
- Coverage expansion and clinician familiarity could enhance penetration, pushing annual sales toward $3–3.5 billion by 2024.
Medium-Term (3-5 years)
- Growth could slow to 8–12%, balancing market saturation with emerging competitors.
- The inclusion of adolescent and adult indications may open additional markets, adding an estimated $0.5–1 billion in revenue.
Long-Term (5+ years)
- Potential for market maturation with sales plateauing around $4 billion annually.
- Price pressure may ensue due to negotiations and biosimilar development, though no biosimilar pathway exists for gene therapies currently.
Price Projections
| Year |
Estimated Price (if unchanged) |
Key Drivers |
Caveats |
| 2023 |
$2.1 million |
Stable manufacturing, market acceptance |
Reimbursement negotiations, price sensitivity |
| 2024 |
$2.1 million or slight decrease |
Payer negotiations, competitive pressure |
Biosimilar emergence unlikely in near future |
| 2025 |
$2 million–$2.2 million |
Long-term contracts, volume discounts |
Potential for price adjustments based on clinical data and policy changes |
Influencing Factors on Future Pricing
- Regulatory Decisions: Approval of expanded indications, such as for older SMA patients, could influence pricing.
- Market Competition: Development of alternative therapies or biosimilars could drive prices down.
- Reimbursement Policies: Payer acceptance, value-based pricing models, and risk-sharing agreements will shape actual transaction prices.
- Manufacturing Costs: Any shifts in production complexity or scale may impact cost structures and pricing.
Key Takeaways
- NDC 58914-0501 (Zolgensma) commands a premium price point of roughly $2.1 million per dose, justified by its one-time administration and potential for lifelong benefit.
- Significant market growth is anticipated, driven by increasing diagnosis rates and expanded indications, with sales potentially reaching $3–4 billion annually within five years.
- Price stability remains probable in the short term but could be affected by negotiations, competition, and policy interventions.
- Emerging data on long-term outcomes may influence future reimbursement and pricing strategies.
FAQs
1. Will Zolgensma's price decrease in the near future?
Potentially, if biosimilars or competing therapies emerge, or payer negotiations lead to discounts. However, as a gene therapy with no current biosimilar pathway, immediate reductions are unlikely.
2. How does Zolgensma compare with Spinraza in market value?
Zolgensma's single-dose treatment has higher initial costs but simplifies administration, appealing to payers. Spinraza, requiring ongoing injections, incurs higher lifetime costs.
3. Are there prospects for expansion into adult SMA markets?
Yes, ongoing clinical trials and regulatory submissions aim to expand indications, which could significantly increase market size and revenues.
4. What factors could impact reimbursement strategies?
Clinical outcomes data, patient access negotiations, and health technology assessments influence reimbursement: value-based agreements are increasingly common.
5. What are the main risks to Zolgensma's market growth?
Regulatory delays, emergence of alternative gene therapies or biosimilars, and unfavorable reimbursement policies could limit growth.
References
- FDA. (2019). Zolgensma (onasemnogene abeparvovec-xioi) approval document.
- Novartis. (2022). Financial report and sales data on Zolgensma.
- SMA Foundation. (2022). Incidence and treatment landscape.
- IQVIA, "Global Oncology Drug Market Analysis," 2022.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for gene therapies.
[1] FDA. Zolgensma Approval.
[2] Novartis Financial Disclosures, 2022.
[3] SMA Foundation Data, 2022.
[4] IQVIA Market Reports, 2022.
[5] CMS Reimbursement Guidelines, 2022.
